<DOC>
	<DOCNO>NCT01281943</DOCNO>
	<brief_summary>This Phase II study use MTD previous Phase I study recommend dose combination regimen Phase I trial , Doxil 25mg/m2 IV Q 4 week temsirolimus 25mg IV Q week .</brief_summary>
	<brief_title>Study Pegylated Liposomal Doxorubicin Temsirolimus Patients With Advanced Hepatocellular Cancer</brief_title>
	<detailed_description>This proposal aim capitalize consensus recommendation NCI panel , know antitumor activity doxorubicin HCC , yet unpublished result recently complete Phase I clinical trial ( WU HRPO # 07-0447 , NCT00703170 ) combine pegylated liposomal doxorubicin ( Doxil® ) temsirolimus ( Torisel® ) patient advance solid tumor . In Phase I study , twenty-two patient enrol treat . The MTD recommend Phase II dose combination regimen trial Doxil 25mg/m2 IV Q 4 week temsirolimus 25mg IV Q week . During conduct study two patient experience confirm partial response ( PR ) . One patient heavily pretreated metastatic breast cancer remain study 6 month . The second patient PR HCC previously treat sorafenib . She remain study regimen 14 month tolerate treatment well . Based tolerability drug combination observe anti-tumor activity HCC , current Phase II study HCC propose .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Histologic Diagnosis : Patients must histologically cytologically proven hepatocellular cancer ( HCC ) amenable treatment via resection liver transplantation . In absence tissue diagnosis , nodule CT characteristic appearance HCC plus Alpha Fetoprotein ( AFP ) &gt; 400ng/ml consider diagnostic HCC . Measurable Disease : Patients must measurable disease . Measurable lesion define accurately measure least one dimension ( long diameter record ) ≥20 mm conventional technique ( PET , CT , MRI , xray ) ≥10 mm spiral CT scan . All tumor measurement must record millimeter ( decimal fraction centimeter ) . A positive bone scan , osteoblastic metastasis , pleural peritoneal effusion consider measurable . Patients lesion eligible entry study . Prior Therapy : Patients may may receive prior systemic therapy metastatic setting . No prior treatment mTOR inhibitor doxorubicin permit . Participants must recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . No chemotherapy radiotherapy may give within 4 week prior start protocol treatment . Age : Patients must ≥18 year old . Because dose toxicity data currently available use temsirolimus combination pegylated liposomal doxorubicin patient &lt; 18 year age , child exclude study . Performance Status : ECOG 02 study entry . Life Expectancy : Patients must life expectancy great 12 week . Required Laboratory Values : absolute neutrophil count ≥1,500/mm3 platelets ≥100,000/mm3 hemoglobin ≥9.0 g/dL total bilirubin ≤1.5 x ULN AST ( SGOT ) /ALT ( SGPT ) ≤1.5 x ULN ( ≤2.5 x ULN patient liver metastasis ) alkaline phosphatase ≤2.5 x ULN creatinine ≤1.5 x ULN OR creatinine clearance ≥60 mL/min/1.732 patient creatinine level 2.0 mg/dl serum cholesterol ≤350 mg/dL /9.0 mmol/L ( fast ) triglyceride ≤400 mg/dL ( fast ) * albumin ≥3.0 mg/dL Patients triglyceride level &gt; 400 mg/dL start lipid lower agent reevaluate within 1 week . If level go ≤400 mg/dL , consider trial continue lipid lowering agent . ChildPugh ( CP ) A B liver dysfunction eligible unless bilirubin &gt; 1.5 x ULN . If noncontraindicated , hepatic impairment ( bilirubin &gt; 11.5 x ULN AST &gt; ULN bilirubin ≤ULN ) present patient treat low dose ( 15 mg/week ) temsirolimus . Concomitant Medications : Temsirolimus primarily metabolize CYP3A4 . Patients receive enzymeinducing antiepileptic drug ( EIAEDs ; e.g. , phenytoin , carbamazepine , phenobarbital ) CYP3A4 inducer rifampin St. John 's wort , may decrease temsirolimus level . A partial list agent interact cytochrome P450 ( CYP3A ) find Appendix B . Use agent potently inhibit CYP3A ( hence may raise temsirolimus level ) , ketoconazole , discourage , specifically prohibit . Temsirolimus inhibit CYP2D6 , may decrease metabolism ( increase drug level ) drug substrates CYP2D6 , codeine . The appropriateness use agent leave physician discretion . A list drug may potential interaction CYP2D6 find Appendix A . If doubt eligibility base concomitant medication , Principal Investigator contact . All concomitant medication must record . Known Allergies : Patients know hypersensitivity reaction macrolide antibiotic ( erythromycin , clarithromycin , azithromycin ) eligible trial . Cardiac Function : Patients must normal leave ventricular ejection fraction ( LVEF ≥50 % ) MUGA scan . Sexually Active Patients : For sexually active patient , use adequate contraception ( hormonal barrier method birth control ) require prior study entry duration study participation . Nonpregnant status determine woman childbearing potential . Pregnant nursing woman eligible . HIVPositive Patients : Patients receive antiretroviral therapy ( HAART ) HIV infection exclude study possible pharmacokinetic interaction . Appropriate study undertake patient receive HAART therapy , indicate . Neurologic Status : Patients must active CNS disease . Recovery Intercurrent Illness : Patients must recover uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris cardiac arrhythmia . Informed Consent : Patients must sign Washington University Human Research Protection Office ( HRPO ) approve informed consent . The patient serious medical psychiatric illness would prevent either give informed consent receipt treatment . Inclusion Women Minorities : Entry study open men woman racial ethnic subgroup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>